Les médicaments orphelins commercialisés en France (2001-2005) : information officielle et spécificités

Reimbursed Orphan Medicines in Bulgaria and the Share of Biotechnology-Derived Products

“…the medicines intended for treatment of rare diseases are called "orphans" because the pharmaceutical industry has little interest, under normal market condition, in developing and marketing products intended for only a small number of patients suffering from very rare conditions (1,2,3,4,5,9,11). Almost 80% of the rare diseases have identified genetic origins and a lot of them are treated with biotechnologyderived medicinal products.…”